Tagged with MSD

Singapore As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other markets. This situation keeps the Health Sciences Authority (HSA) – the country’s regulatory body – extremely busy. While challenges, including…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Singapore MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a…

Global Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines. Moreover, vaccines are an important part of these companies’ revenue streams, making up between 13 and 21 percent of total revenues in 2019.   Made with Visme Infographic Maker   Insights on Vaccines’…

Vaccines While outbreaks of the devastating Ebola virus have – thankfully – generally been highly localized to West Africa, the highly infectious and lethal disease has generated global trepidation due to its characteristic haemorrhagic fever, a 50 percent chance of death on average, and the absence of any approved treatment. The…

Coronavirus During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA; Roche CEO Dr Severin Schwan, also vice-president of IFPMA; Pfizer chairman and CEO Dr Albert Bourla; MSD (Merck & Co.…

Coronavirus Top global pharma executives involved in the development of COVID-19 vaccines have stated their commitment to not rushing the release of any potential vaccine without it passing through the full clinical trial process and proving to be safe and effective. Albert Bourla of Pfizer and Kenneth Frazier of Merck (MSD…

Norway The top 10 pharma companies in Norway ranked by 2019 turnover according to IQVIA data. The Norwegian market is dominated by multinationals, with Finnish Orion Pharma the sole Nordic representative in the top 10 list. See below for the full rankings.   Novartis Swiss firm Novartis had a turnover of…

Norway The Top 15 pharmaceutical companies in Norway ranked by sales turnover in 2019. The market is dominated by multinationals, with Novartis, Pfizer and MSD making up the top three positions.   Made with Visme Infographic Maker  

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Rankings The top 10 of Pharmaceutical Exec’s Top 50 Companies 2020. Roche overtakes Pfizer to take the number one spot, followed by Novartis which moves up from third to second on the list. For the full list and extensive analysis, see the Pharma Exec website here.   Made with Visme Infographic Maker